Hymenoptera venom allergy (HVA) is the most frequent cause of anaphylaxis in Europe, accounting for most of the severe reactions occurring in adults and being the second cause of anaphylaxis in children. Prevention of further episodes in patients who developed a systemic reaction (SR) is based on the correct management of the allergic emergency, the referral to an allergist for a correct diagnosis, prescription of adrenaline auto-injectors (AAI) and specific venom immunotherapy (VIT), if recommended. Diagnosis is based on the classification of the type of reaction, confirmation of an IgEmediated pathogenesis and the identification of the offending insect. The use of component resolved diagnostics may be helpful in case of poly-sensitization or negative allergy tests with a proven history of previous SRs. When a severe SR occurs, baseline serum tryptase levels should always be assessed. The prescription of AAI is recommended or suggested for untreated patients, patients undergoing VIT and after discontinuation of treatment, according to multiple evidence. VIT is the most effective treatment available for HVA patients, as confirmed by recent European guidelines. VIT has an early, sustained and persistent protective effect and modifies the natural course of the disease. Moreover, VIT proved to be safe and well tolerated. According to a recent systematic review, no treatment-related fatalities were recorded to date. Compared to AAI, VIT significantly improves the quality of life of HVA patients by reducing the anxiety and limitations in daily activities caused by the fear of stinging insects. The memory of a life-threatening experience is the most likely reason why adherence to VIT is higher compared to immunotherapy with inhalant allergens. Several risk factors in HVA have been identified that can influence not only the severity of sting reactions in untreated patents, but also the occurrence of side effects, treatment effectiveness and the risk of relapse after discontinuation of VIT. Patient and treatment-related risk factors must be considered while selecting the best candidates Dear Editors, My fellow colleagues and I are pleased to submit our focused review entitled "Clinical Aspects of Hymenoptera Venom Allergy and Venom Immunotherapy" for your consideration for publication in Annals of Allergy and Clinical Immunology.
Introduction 1 2
Hymenoptera venom allergy (HVA) is a potentially life-threatening allergic condition 3 frequently observed in the general population. In Europe, the prevalence of systemic 4 reactions in the adult population is 0.3-8.9%, being lower in children and higher in 5 beekeepers (1). According the European Anaphylaxis Registry, HVA is the major cause of 6 anaphylaxis in adult subjects (48.2%), while it accounts for 20.2% of anaphylactic episodes 7 in pediatric patients (2). 8 Stinging insects that most frequently cause HVA in developed countries are bees of the 9 Apidae family and wasps of the Vespidae family. Among bees, the most commonly observed 10 stinging species that causes HVA is the common bee (Apis mellifera), while among wasps, 11 several species of both Vespinae (i.e. Vespula spp., Dolichovespula spp., Vespa spp.) and 12 Polistinae (i.e. Polistes dominula, Polistes annularis) subfamilies cause allergic reactions. 13 Venoms produced by Red Wood ants (Formica rufa) and Fire ants (Solenopsis invicta), 14 usually found in rural areas of North and Central America, and Australia, although sporadic 15 in Europe, are also potent sensitizing agents and cause of allergic reactions upon biting (3). 16 Allergens of bee and vespids venoms are summarized in Table 1 . 17 Given its unpredictable nature, patients with HVA usually have a poor quality of life, even in 18 the case of a mild severe reactions (SR) (4). 19 It is especially daunting to properly diagnose patients with HVA, choose the right treatment 20 and manage the long-term follow-up. Furthermore, there are several risk factors for SR that 21 must be taken into consideration, from the diagnosis to the discontinuation of treatment, that 22 might complicate HVA treatment and management and are often unrecognized. 23 The purpose of this review is to provide to clinicians relevant and updated information on 24 HVA diagnosis, clinical management and treatment in adult and pediatric populations, with 25 special interest to high-risk HVA patients, and suggestions on how to manage HVA 26 effectively in daily practice.
28
Methods 29 30 We performed a PubMed search for most relevant state-of-the-art guidelines, position papers, 31 reviews, expert opinions and articles, with focus on clinical aspects, diagnosis, self-treatment 32 and management of acute reactions, specific venom immunotherapy and long-term 33 management of HVA. 34 35 Results and Discussion 36 37 1. Clinical aspects and diagnosis of HVA 38 39 1.1 Collection of clinical history 40 41 In HVA it is of vital importance to collect as many relevant information to formulate a 42 correct diagnosis, but also aimed at recognizing potential risk factors that might increase the 43 risk of severe reactions (5). 44 Information on the stinging insect, although challenging and sometimes misleading, is helpful 45 to guide the diagnosis and the selection of VIT. A detailed history of the stinging event (i.e. 46 number of stings, previous and subsequent re-stings), with questions on the appearance and 47 behavior of the insect (day/night encounter, information on hives/nests) and the type of sting 48 (i.e. extraction of sting; death of offending insect), when available, should be documented 49 from each subject. Information on occupational or recreational activities linked to a higher 50 M a n u s c r i p t a c c e p t e d f o r p u b b l i c a t i o n likelihood of sting (e.g. farmers, beekeepers, outdoor sports) are also important pieces of 51 information to collect, guiding the treatment strategy and future management (5). 52 The type of elicited reaction is also a crucial step during the collection of the clinical history 53 from HVA patients: reactions are divided in large local (LLR) and systemic, according to 54 the extent of involvement. Usually the toxic local reaction induced by venoms is transient, 55 self-limiting and completely resolving in less than 24-48 hours; in allergic patients, LLRs 56 are defined as edema exceeding 10 cm in diameter, increasing within 24-48 hours after the 57 sting, and lasting longer than 72 hours (5). 58 LLRs, although worrisome for HVA patients, have a low risk of evolution in SR (2-7%), 59 especially in case of repeated LLRs (6,7), even though a recent paper on a large population 60 shows that the risk of a SR, after a previous LLR, occur more frequently than that reported 61 by previous literature (8) . LLRs should not be underestimated if causing reduced quality of 62 life, or when the risk of multiple simultaneous stings is high (i.e. beekeepers, farmers). 63 Allergic SR may involve one or more organ systems (i.e. cutaneous, respiratory, 64 gastrointestinal, neurologic and cardiovascular systems), while the simultaneous 65 involvement of two or plus organ systems during an acute allergic event is diagnostic for 66 anaphylaxis (9-11). 67 Cutaneous involvement (e.g. acute generalized urticaria/angioedema) is more frequently 68 observed in both adults and children, accounting for 80% and more than 90% of HVA 69 reactions, accordingly (5,12). Respiratory involvement (e.g. bronchospasm, acute upper 70 airway obstruction due to angioedema) is observed in around half of SRs (5). As for the 71 involvement of the cardiovascular system, hypotension (60% of cases) and loss of 72 consciousness (50%) might occur independently of other associated symptoms, especially in 73 case of systemic indolent mastocytosis, and are more frequently observed in adults than 74 children (13). Gastrointestinal involvement (e.g. vomiting, diarrhea, abdominal pain, 75 nausea), uterine cramps (with possible miscarriage) and neurologic symptoms (e.g. 76 dizziness, convulsions) are also reported (13). Other symptoms like rhabdomyolysis, 77 disseminated intravascular coagulation, intravascular hemolysis, acute hepatic and renal 78 failure might also occur, and are generally due to direct toxic effects of hymenoptera venom 79 (5). 80 It is important to also investigate the recurrence of symptoms after 4-12 hours from the 81 resolution of the first anaphylactic episode, without re-exposure to stings, since biphasic 82 anaphylaxis is reported in 0. Both skin tests and serologic tests should be performed in patients with a positive history of 106 systemic reactions. In patients with LLRs, diagnostic tests can be optionally performed, 107 especially when bothersome or with high risk of recurrence, possibly to start VIT (5,31,32). 108 They are not recommended for screening the general population, since 10-30% of subjects 109 without any previous history can be found positive (13, 19, 31, 33 ) . 110 Skin tests are safe to perform even in subjects with history of severe anaphylaxis or with 111 clonal mast cell disorders, if executed by experienced professionals in a hospital setting with 112 access to emergency care (22, 34) . 113 The gold standard for HVA diagnosis is skin testing with venom extracts, which should be 114 performed not less than two weeks after the last sting to prevent false negative tests due to the 115 refractory period (5, 19, 31) . 116 Skin prick test (SPT) at 100 µg/mL concentration can be used as first assessment for HVA. 117 Cut-off for positivity is the appearance of a wheal of ≥ 3 mm diameter compared to the 118 negative control in the pricked area after 15-20 minutes (35). Regardless of SPT results, it is 119 recommended to also perform intradermal testing (IT); briefly, venom extracts, serially 120 diluted to reach end concentrations ranging from 0.001 to 1 µg/mL, are administered at 121 increasing concentrations with intradermal needle injection (5). The test is stopped at the 122 concentration causing the formation of a wheal (threshold concentration) after 15-20 minutes, 123 or when reaching 1 µg/mL concentration, since higher concentrations of venom extracts 124 might exert an irritant effect (36). Multiple venoms can be assessed at once, given that the 125 same concentration is used (13). The outline of the positive wheal reaction should be marked 126 with a drawing pen, transferred to paper using transparent tape and stored in clinical records 127 for both diagnostic and VIT monitoring purposes (37). 128 The sensitivity of SPT alone is estimated around 64%, while a combination of SPT and IT 129 reaches a 94% sensitivity, hence it is recommended to perform both tests sequentially, when 130 available (5,19,31). 131 In case of negative skin tests but presence of a suggestive history of SR, cutaneous tests 132 should be repeated after 1-2 months, along with serologic testing. 133 As for other in vivo tests, it is recommended to refrain from using the sting challenge with a 134 live insect for diagnostic purposes, since this procedure is at high risk for severe reactions and 135 has low negative predictive value (38). 136 137 138 139 The detection of specific IgE antibodies is an important step for HVA diagnosis to improve 140 the diagnostic accuracy, therefore current guidelines recommend performing both skin and 141 serologic tests (5,19,31). 142 IgEs are antibodies produced after the very first sensitizing event and can be detected 143 immediately in the serum after the first allergic reaction, although it is recommended to 144 determine their levels 1-4 weeks after the last sting (13). 145 Sensitivity of serological tests is different according to the type of venom tested: typically, 146 the detection of specific IgEs against Vespula spp. is less sensitive than Apis mellifera's, 147 showing 83-97% and 98-100% sensitivity, respectively (39-41). When the stinging insect cannot be identified, and skin and/or serologic tests show positivity 162 to multiple venoms (i.e. Vespula spp. and Apis Mellifera in 25-40% of the cases, Vespula spp. 163 and Polistes spp. in over 50% of cases), it is important to discriminate between cross- Conversely, the discrimination between Vespula spp. and Polistes spp. sensitization is more 183 challenging, due to high phylogenetic overlap between the two species, for which CRD 184 testing has proven to be less efficient (47-49). In clinical practice, assessing serum levels of 185 Ves v 5 and Pol d 5 is considered helpful to discriminate between sensitizations, given that 186 the levels of one recombinant allergen is at least double than the other (52,53). However, a 187 recent study showed that such proposed ratio was less accurate than CAP-inhibition and 
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Treatment and management of HVA
223
After an appropriate diagnosis of HVA, it is of utmost importance to provide patients both a 224 strategic plan to manage acute reactions upon re-sting and a long-term management plan, to 225 reduce the occurrence of severe reactions, by adopting avoidance measures and prescribing 226 immunotherapy with specific venoms.
228
3.1. Self-treatment and management of acute episodes 229 230 In the management of an acute allergic reaction, it is vital that the patient, caregivers and/or 231 parents, have been adequately informed and trained on recognizing the early signs and 232 symptoms of anaphylaxis, on the use of self-medication treatments to be administered 233 without any delay or hesitation, and the precautionary actions to be performed after resorting 234 to self-treatment (10). 235 Self-medication is the mainstay for the treatment of acute events, since in most cases the re-236 sting occurs outdoors, distant to emergency departments, and the quick onset of symptoms 237 after stinging requires immediate treatment to avoid severe, and sometimes fatal outcomes. 238 The type of treatment may differ according to the severity of the acute allergic reaction. To date, the only disease-modifying treatment for HVA is VIT; VIT is a safe and effective 310 therapy, capable of inducing selective tolerance to specific venoms (protection against 311 vespids reported in 91-96% of cases, 77-84% for bee allergy (32). Nonetheless, VIT offers 312 long lasting protection upon re-sting even after discontinuation of treatment, and increases 313 dramatically the quality of life of HVA patients (19,32,33, 63). 314 VIT is currently indicated for treating the following adult and pediatric subjects: The VIT protocol should be flexible, to accommodate both patients' and clinicians' 350 necessities; for instance, switching from aqueous to depot formulations of the same 351 manufacturer can be easily done, without any reduced safety or efficacy for the patient (89). 352 In case of shortage of venom extracts, the switch to another manufacturer can be performed 353 safely, according to a recently proposed switch protocol using the same maintenance dose in 354 subjects that previously tolerated a long-term VIT, while in case of documented SR during 355 VIT, a safe option is to restart VIT from the build-up phase (90,91). 356 Once maintenance dose is reached, recommended administration interval is 4 weeks for the 357 first year of VIT, and slowly increased up to 6-8 weeks (or 12 weeks, according to some The protection induced by VIT is also responsible for the increased perceived quality of life 369 in treated patients, even compared to AAI prescription alone (77,97). 370 However, therapeutic failure in VIT might still occur, and is more frequently observed in 371 adults rather than children (13,32,63). The appearance of a large local reaction at the administration site is not correlated with an 394 increased risk of subsequent adverse events and therefore no dose adjustments are required. 395 Conversely, the appearance of a SR requires to step down and temporarily to continue VIT 396 M a n u s c r i p t a c c e p t e d f o r p u b b l i c a t i o n with the last tolerated dose (32). Pre-treatment with anti-histamines was shown to reduce 397 local and mild systemic adverse reactions, increasing VIT tolerability without compromising 398 its efficacy, and is currently recommended by EAACI guidelines (32). However, expert 399 panels suggest it as optional, due to the risk of masking warning signs of SR, especially when 400 using rush and ultra-rush protocols (13). Omalizumab might also be used as premedication 401 strategy in subjects experiencing SR during VIT, although its use is still off-label (32). 402 Treatment with VIT can be safely discontinued when both skin and serologic test are sting challenges offer important information on the effectiveness of VIT in preventing SR; 408 however, they do not occur in every VIT treated patient, due to avoidance strategies, 409 therefore the current gold standard is the sting challenge with live insects to be performed in 410 specialized centers. The sting challenge, although useful, is a procedure that poses both 411 ethical and management problems in some countries and is therefore difficult to perform (13). 412 Practical considerations for VIT in clinical practice are listed in Table 3 . The appropriate diagnosis, treatment and management of HVA is important to modify the 438 natural course of the disease and increase dramatically the quality of life of affected patients. 439 Recognizing specific risk factors for severity and treatment failure, and knowing the strengths 440 and weaknesses of diagnostics and currently available treatments should make dealing with 441 HVA a less daunting task.  The standard maintenance dose to be administered is 100 μg of venom. If patients still react to field stings or sting challenge, a dose increase to 200 μg of venom can be recommended.
Adverse reactions
 Purified venom preparations have a lower frequency of local and systemic adverse events than non-purified aqueous preparations.
Dosing interval  VIT injections should be administered every 4 weeks in the first year of treatment, every 6 weeks in the second year, and in case of a 5-year treatment, every 8 weeks from year 3-5. In the case of lifelong therapy, 12-week intervals may be still safe and effective.
Duration of VIT
 VIT should be performed for at least 3 years. In patients with severe initial sting reactions, at least a 5-year treatment is recommended.  Lifelong VIT may be recommended in highly exposed patients with bee venom allergy, patients with very severe initial sting reactions, patients with systemic side-effects during VIT, and patients with mast cell disease.
Risk factors
 Patient-related as well as treatment-related risk factors must be taken into account, and patients with one or more risk factor should be treated and monitored with special care. 
